Molly Schmid

Current Institution
Senior Business Consultant
California Small Business Development Center

Scholar: 1986

Awarded Institution
Princeton University


Research Interests

Dr. Schmid's research at KGI combines two distinct areas of interest: antimicrobial drug discovery and innovation in the pharmaceutical industry and its challenges. The combination of these two areas gives KGI students real life scenarios of challenges that pharmaceutical companies face. Dr. Schmid's teaching and research focuses on how to make drug discovery faster, less risky and less expensive.

While an Assistant Professor of Molecular Biology at Princeton University, her research group discovered Topoisomerase IV in Salmonella typhimurium as well as a genetic strategy for identifying new antimicrobial targets. She is continuing her search for antimicrobial drugs at KGI.

Current Research Projects

Managing New Product Development in the Pharmaceutical Industry: Dr. Schmid's research efforts aim to better understand the lack of research productivity in the pharmaceutical industry. She has created methods allowing the identification and characterization of failed discovery-stage pharmaceutical projects, a subject that is typically difficult to measure and not often discussed. This information provides a measure of early stage research activities occurring in pharmaceutical companies. This analysis is used to assess the key bottleneck points in the pipelines of pharmaceutical companies and to assess project management decision-making during the lengthy, failure-prone pharmaceutical R&D process.

Fail Early-Fail Fast Decisions in Pharmaceutical New Product Development (in collaboration with J. Darroch, Ito & Drucker School of Management, Claremont Graduate University): Dr. Schmid has created a method to measure pharmaceutical failure rates by measuring "innovation litter," and is developing and applying metrics to measure "fail early, fail fast/fail cheap" (FEFF) decision-making. These steps will determine the shape of the drug discovery and development pipeline. By applying these methods, pharmaceutical discovery managers may better allocate R&D resources for optimum effectiveness. Efficiencies adopted by companies in this stage of the pharmaceutical new drug development process may provide an enormous opportunity for achieving a competitive advantage for the innovating firm.

Antimicrobial Drug Discovery: Professor Schmid's lab is combining old and new approaches to the search for promising lead compounds that can enter the antimicrobial drug development pipeline. She is partnering with academic and industrial collaborators in the US and Canada to identify and characterize novel molecules that have potential to be new antimicrobial agents. Her approaches combine new methods in structure-guided drug discovery, with genetic and genomic methods for target identification and validation.